Abstract: A composition, for application to a surface of keratin, including a first polyesteramine, is disclosed. The first polyesteramine is a first conditioning agent present in an amount ranging from 0.1% to 99.9% by weight of the composition. The composition also includes a second polyesteramine. The second polyesteramine is a second conditioning agent present in an amount ranging from 0.1% to 99.9% by weight of the composition.

Abstract: A composition comprising an edible oil comprising coconut oil, palm kernel oil, palm oil, sunflower oil, hemp seed oil or any combination thereof; an edible triglyceride comprising cocoa butter, mango butter, ghee, hydrogenated palm oil, or any combination thereof; a humectant comprising glycerin, polyethylene glycol, propylene glycol, sorbitol, xylitol, maltitol, or any combination thereof; a binder comprising maltodextrin, sucrose, microcrystalline cellulose, pregelatinized starch, dextrose, lactose, or any combination thereof; and one or more flow aids.

Abstract: The present invention is in the field of antiperspirant compositions, in particular, compositions comprising antiperspirant actives. Disclosed is an antiperspirant composition comprising (i) at least one hydrophobic sorbitan ester having HLB value between 1 and 7.0; (ii) at least one hydrophilic sorbitan ester having HLB value between 7.0 and 20; (iii) at least one organic compound selected from C7-C24 fatty acid, or C7-C24 fatty alcohol; and (iv) a cosmetically acceptable carrier; wherein said composition comprises less than 50% of water; wherein said composition comprises at least 2% said hydrophobic sorbitan ester by weight of the composition; wherein the weight ratio of organic compound to the combination of the hydrophobic sorbitan ester and the hydrophilic sorbitan ester is from 1:10 to 5:1; wherein the composition is free from antiperspirant active which comprises aluminium or zirconium.

Abstract: The present invention relates to a suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and/or salts thereof.

Abstract: An agent for dyeing keratinous material, such as human hair, may include: at least alkylene glycol of formula (AG) where x is an integer ranging from 1 to 10,000. The agent may further include at least one pigment and at least one amino-functionalized silicone polymer.

Abstract: The present disclosure provides a method for the treatment or prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in a cancer patient treated with, or to be treated with, a CIPN causing chemotherapeutic agent, the method comprising: administering a therapeutically effective amount of a composition containing a peptide amphiphile lipid micelle (PALM) nanoparticle to the cancer patient, the PALM nanoparticle comprising a PALM containing the CIPN causing chemotherapeutic agent, and wherein the PALM comprises a peptide, and a lipid component comprising sphingomyelin and one or more additional phospholipids.

Abstract: The present invention relates to a water-in-oil solid cosmetic composition stably containing an aqueous phase and an oil phase, and the water-in-oil solid cosmetic composition can be implemented as a stable formulation by containing the aqueous phase and the oil phase at an appropriate ratio, and has effects of causing no skin troubles, having reduced stickiness, and providing an improved moisturizing feeling by containing a large amount of water-soluble ingredients instead of silicone and other non-aqueous raw materials in the conventional art.

Abstract: Disclosed herein is directed to cationic lipids and lipid nanoparticles (LNPs) comprising the same for encapsulating and delivering active pharmaceutical ingredients (API) (e.g., nucleic acids) into cells. The cationic lipid has the structure of formula (I), wherein, at least one of X and Y is —(C?O)CH2NH2, and the other X, Y, and Z are independently selected from the group consisting of —(C?O)CH2NH2, —[C?O)CH2NH](C?O)R1, —(C?O)R1, and H, wherein R1 is C9-25 alkyl, or C13-21 alkenyl. Also encompasses herein is a method of treating a disease in a subject in need thereof, comprising administering an effective amount of the LNPs set forth above to the subject.

Abstract: Compositions, devices, and methods related to determining adequacy of the application of a sunscreen composition on human skin are disclosed. A disclosed sunscreen composition includes a sunscreen agent and a fluorescent agent, which, when excited by an ultraviolet light having a compatible wavelength, fluoresces in visible light. A method for determining whether the sunscreen composition has adequately applied on human skin is disclosed. A disclosed device generates an ultraviolet light having a compatible wavelength and is portable.

Abstract: A composition suitable as coating or binding agent for pharmaceutically, nutraceutically or cosmetically active ingredients includes: a) at least one (meth)acrylate copolymer a), including polymerized units of 5-25% by weight of methacrylic acid and 75-95% by weight of C1-4-alkylesters of methacrylic acid and/or C1-4-alkylesters of acrylic acid, and b) 1-25% by weight, based on the total weight of at least one (meth)acrylate copolymer a), of an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid having 10 to 30 carbon atoms, and c) or d) or both c) and d) c) 2-25% by weight, based on the total weight of a), of at least one compound selected from glyceryl tristearate, hydroxypropyl methylcellulose, glyceryl behenate, and glyceryl monostearate and/or d) 25-90% by weight, based on the total weight of a), of at least one selected from talc, rice hulls in powder form, magnesium stearate, corn starch, and microcrystalline cellulose.

Abstract: Methods for treating or preventing mitochondrial dysfunction are disclosed. Methods for treating or preventing a disease or condition associated with mitochondrial dysfunction or a symptom thereof are disclosed. Methods for treating or preventing an aging-associated chronic disease or condition related to mitochondrial dysfunction or a symptom thereof are disclosed. Methods for improving or preventing a decrease in energy level and/or vitality are disclosed. The methods include administering an emblica extract or a compound constituent of an emblica extract, or fucus extract or a compound constituent of a fucus extract, or a chebula extract or a compound constituent of a chebula extract.

Abstract: The invention provides a formulation and method for the treatment of urinary system disorders, wherein the formulation comprises a controlled release drug delivery system for intravesicular administration to a patient. Controlled release microparticles in the formulation are comprised of a pharmacologically active agent and a controlled release carrier, where the microparticles are buoyant in urine. Microparticle buoyancy in urine ensures that the formulation continues to release the active agent into a patient's bladder throughout the duration of an extended drug delivery time period. Methods of treating urinary system disorders by intravesicular administration of the microparticle formulation to a subject are also provided, and include methods of treating urinary system infections, bladder cancer, incontinence, and other urinary system disorders.

Abstract: Liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof are described. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 3-8 over a variety of storage conditions, including long-term storage for extended periods of time. Various methods for preparing stable liquid pharmaceutical compositions of baclofen are described. Methods of treating spasticity using the inventive pharmaceutical compositions are also provided.

Abstract: The present disclosure relates to compositions comprising freeze-dried fruit and/or vegetable component and active ingredient wherein the active ingredient is conserved. The present disclosure further relates to methods for preparing the freeze-dried fruit and/or vegetable based compositions for active ingredient delivery.

Abstract: The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

Abstract: The present invention relates to a process for loading a polymer with an active pharmaceutical ingredient in a melt granulation process and to the prepared product. More specifically the invention relates to a process of preparing granules which contain at least one active pharmaceutical ingredient and polyvinyl alcohol.

Abstract: Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

Abstract: Disclosed herein are dosage forms including a fill material that incorporates an anionic chelating agent, such as lecithin, and a salt form of a basic or acidic active pharmaceutical ingredient and a free ion. The molar ratio of the anionic chelating agent, such as lecithin, to the free ion ranging from about 0.5 to about 3. Also disclosed herein are methods of stabilizing dosage forms that include a salt form of a basic or acidic active pharmaceutical ingredient, methods of preparing such dosage forms, and methods of using such dosage forms.

Abstract: To provide a stabilized preparation for using Araliadiol as a medicine or a functional food, and a method for manufacturing the same. A powdery preparation that contains Araliadiol, dextrin and cyclodextrin. Preferably, the powdery preparation further contains a macromolecular polysaccharide.

Abstract: Provided herein are compositions and methods for delivering pharmaceutical agents to the kidney. In particular, provided herein are nanoparticle formulations of ?2 adrenergic agonists for use in treating and preventing kidney damage or disease.